Cardlytics, INC

Cardlytics, Inc. has implemented a 1-for-10 reverse stock split and reduced authorized shares to address Nasdaq's minimum bid price requirement, with a compliance deadline of November 30, 2026.

Cardlytics, Inc. held its Annual Meeting on May 20, 2026, where shareholders elected directors, ratified the auditor, approved a potential reverse stock split, and voted on executive compensation.

Cardlytics, Inc. announced the resignation of its Chief Legal and Privacy Officer, Nick Lynton, with a transition agreement outlining severance and continued services.

Cardlytics, Inc. has completed the sale of its Bridg platform to PAR Technology Corporation, receiving 1,810,222 shares of PAR common stock as consideration.

Cardlytics announced its fourth quarter and full year 2025 financial results, showing mixed performance with revenue declines but improved adjusted profitability, alongside a challenging Q1 2026 outlook.

Cardlytics, Inc. has entered into an agreement to sell its Bridg platform to PAR Technology Corporation for up to $30 million in PAR common stock.

Cardlytics reports a significant net loss and revenue decline in Q3 2025, driven by a substantial goodwill impairment and reduced billings, alongside a workforce reduction plan.

Cardlytics reports a decline in Q2 2025 revenue and billings, alongside a significant non-renewal notice from Bank of America, while extending its JPMorgan Chase partnership.

Cardlytics' Q1 2025 results reveal a revenue decrease, influenced by shifts in pricing models and the decommissioning of the Dosh app, alongside strategic financial maneuvers.

Cardlytics' Q3 2024 results reveal a significant goodwill impairment charge impacting overall profitability, despite some growth in user base.

Cardlytics' Q2 results show a decrease in revenue despite an increase in billings, influenced by higher consumer incentives and strategic debt management.

Cardlytics' first quarter of 2024 saw a slight revenue increase alongside strategic debt management and equity offerings.

Cardlytics reports improved Adjusted EBITDA and positive operating cash flow for 2025, despite revenue and billings decline, as Bridg is sold.

Cardlytics' 2024 annual report reveals a decrease in revenue despite growth in monthly active users, highlighting challenges in monetizing its platform and managing costs.

Cardlytics secures lender consent for the sale of HSP EPI assets, amends its loan agreement to increase borrowing capacity, and updates financial covenants.

Christopher Chi-Kit Cheng, Chief Legal & Privacy Officer of Cardlytics, Inc., received 50,000 shares of common stock on August 3, 2026.

Cardlytics CEO Amit Gupta reported transactions involving the sale of company stock following a 1-for-10 reverse stock split.

Nicholas Hollmeyer, Chief Legal & Privacy Officer at Cardlytics, Inc., reported transactions involving the acquisition and disposition of common stock and restricted stock units.

Cardlytics, Inc. director Srishti A. Gupta acquired 11,000 shares of common stock through the vesting of restricted stock units.

Cardlytics, Inc. Director Scott A. Hill reported the acquisition of 11,000 shares of common stock through the vesting of restricted stock units.

Director Andre Fernandez reported the acquisition of 11,000 restricted stock units of Cardlytics, Inc. (CDLX) on May 20, 2026.

Cardlytics announces its 2026 Annual Meeting of Stockholders, proposing a reverse stock split to maintain Nasdaq listing and detailing executive compensation.

Cardlytics has filed a revised definitive proxy statement to include Inline eXtensible Business Reporting Language data tagging that was initially omitted.

Cardlytics, Inc. has filed a definitive proxy statement with the SEC.

Cardlytics has announced its 2025 Annual Meeting of Stockholders to be held on May 20, 2025, outlining proposals including the election of directors, ratification of independent auditors, approval of an equity incentive plan, and an advisory vote on executive compensation.

Cardlytics, Inc. has filed a definitive proxy statement with the Securities and Exchange Commission.

Cardlytics will hold its annual stockholders meeting on May 23, 2024, to elect directors, ratify the selection of independent auditors, and approve executive compensation.

CAS Investment Partners and affiliated entities have updated their beneficial ownership in Cardlytics, Inc. to 9.8% through recent transactions and distributions.

CAS Investment Partners, LLC and its affiliates have filed an amended Schedule 13D, confirming their aggregate beneficial ownership of 11.0% in Cardlytics, Inc. common stock, following recent share distributions and a sale of convertible notes.

The Vanguard Group has filed an amendment to its Schedule 13G, disclosing a 4.60% beneficial ownership stake in Cardlytics Inc. as of June 30, 2025.

BlackRock, Inc. has filed an Amendment No. 6 to its Schedule 13G, disclosing a 2.1% passive beneficial ownership stake in Cardlytics, Inc. as of June 30, 2025.